10x Genomics (TXG) Cash from Financing Activities (2018 - 2026)

10x Genomics' Cash from Financing Activities history runs 9 years deep, the most recent figure standing at -$8.4 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 2094.55% year-over-year to -$8.4 million; the TTM figure through Mar 2026 stood at -$2.0 million (down 120.99% YoY), while the FY2025 annual figure was $6.8 million, down 37.67% from the prior year.
• Cash from Financing Activities came in at -$8.4 million for Q1 2026 at 10x Genomics, down from $2.2 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $7.1 million in Q2 2023 to a low of -$8.4 million in Q1 2026.
• A 5-year average of $2.3 million and a median of $2.4 million in 2022 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities surged 295.51% in 2025 and plunged 2094.55% in 2026, its largest moves.
• 10x Genomics' Cash from Financing Activities stood at $5.0 million in 2022, then grew by 12.24% to $5.6 million in 2023, then declined by 19.53% to $4.5 million in 2024, then plunged by 50.37% to $2.2 million in 2025, then plunged by 475.42% to -$8.4 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$8.4 million, $2.2 million, and $617000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison